Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Raltegravir switch for fatty liver in HIV
NCT02210715Phase 4Completed
- Sponsor
- McGill University Health Centre
- Start
- Mar 2015
- Primary completion
- Jan 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of raltegravir in Nonalcoholic steatohepatitis (NASH), fatty liver disease (FLD) and Liver Fibrosis (LF), sponsored by McGill University Health Centre. Primary endpoint: Improvement of fatty liver at 24 months. Started Mar 2015; status: completed.
02
Drugs
raltegravir
03
Conditions
Nonalcoholic steatohepatitis (NASH)fatty liver disease (FLD)Liver Fibrosis (LF)
Beyond the preview
Go deeper on NCT02210715.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02210715.